Arizona Released Its Annual Substance Use Report. Meth Is Now the Primary Story.

---

title: “Arizona Released Its Annual Substance Use Report. Meth Is Now the Primary Story.” slug: ahcccs-sfy2025-annual-substance-treatment-report post_type: daily_pulse primary_category: arizona-watch lens: [policy, treatment] tags: [arizona, ahcccs, medicaid, methamphetamine, treatment-access, opioids] meta_description: “AHCCCS’s SFY2025 Annual Substance Use Treatment Report documents Arizona’s shift: methamphetamine presentations are now outpacing opioid-primary cases in parts of Maricopa and Pima counties. The evidence-based treatment for meth still isn’t consistently covered.” read_time_minutes: 3 schema_type: NewsArticle sources:

• url: https://www.azahcccs.gov/shared/Downloads/Reporting/2026/AnnualSubstanceUseTreatmentReport-SFY2025.pdf title: “AHCCCS SFY2025 Annual Substance Use Treatment Report” publisher: AHCCCS / Arizona Health Care Cost Containment System source_tier: A published_date: 2026-04-28
• url: https://www.azahcccs.gov/Resources/Grants/GrantsAdministration.html title: “AHCCCS Grants Initiatives” publisher: AHCCCS source_tier: A ai_generated: true

---

On April 28, 2026, AHCCCS Director Carmen Heredia transmitted the agency’s Annual Substance Use Treatment Report for State Fiscal Year 2025 to Governor Katie Hobbs. The report is the most comprehensive picture Arizona publishes each year of who is getting publicly funded substance use treatment, through which programs, and whether the state’s $2 billion-plus behavioral health infrastructure is reaching the people who need it most.

The headline finding, consistent with emerging national trends: methamphetamine is no longer a secondary substance story in Arizona. In parts of Maricopa and Pima counties, meth-primary treatment presentations now exceed opioid-primary cases. The shift has been building for several years—driven by the continued availability and low cost of high-purity methamphetamine from Mexican supply networks and the relative saturation of opioid treatment capacity following years of focused policy investment. Arizona built significant MOUD infrastructure during the 2017–2022 funding surge. That infrastructure is available. The population presenting for treatment has started to outpace it, presenting with a different primary substance for which the treatment system has fewer evidence-based tools.

This is the central tension in the SFY2025 data. Contingency management—a behavioral intervention that uses small, escalating financial rewards to reinforce negative drug tests—has the strongest evidence base of any intervention for stimulant use disorder. Multiple randomized controlled trials have shown it significantly reduces methamphetamine use and increases abstinence rates. Medicaid has not historically covered it, on the grounds that paying people to not use drugs is categorically different from paying for a clinical service. Federal guidance issued in late 2023 opened the door for states to design and submit Medicaid state plan amendments for CM programs; Arizona, as of the SFY2025 reporting period, had not yet implemented a consistent statewide CM benefit through AHCCCS Complete Care plans.

The downstream consequence: Arizona’s providers know what works for meth. Arizona’s payment system does not yet pay for it consistently. The providers doing the most work on stimulant use disorder are running contingency management on grant funding, foundation dollars, and pilot budgets that are not sustainable at the population scale the report’s data implies is needed.

July 2026 brings a separate pressure point: changes to inpatient behavioral health reimbursement under AHCCCS managed care plans, scheduled to take effect at the start of the new state fiscal year. Several inpatient psychiatric and SUD detox programs in the Phoenix metro have raised concerns that rate adjustments could reduce the financial viability of inpatient detox beds at a moment when inpatient behavioral health capacity is already strained—Phoenix has fewer inpatient psychiatric beds per capita than most comparable metros, and wait times for inpatient SUD detox have extended significantly since 2023.

SAMHSA’s January 2026 grant-termination-and-restoration cycle—in which HHS cut and then reinstated $2 billion in addiction and mental health grants within 24 hours—disrupted planning horizons for Arizona programs even at programs whose grants were ultimately preserved. The uncertainty itself has costs: staffing decisions made on the assumption of funding loss are not easily reversed when the funding returns a day later. The SFY2025 report captures the system before those disruptions fully registered; the SFY2026 data will show their impact.

For Arizonans seeking treatment now, the practical landscape: AHCCCS Complete Care plans remain the primary access point, and enrollment is means-tested at income levels that cover a substantial portion of the state population living with substance use disorders. The access gap in Arizona is not primarily an insurance gap—it is a provider capacity gap, a geography gap (treatment access outside metro Phoenix and Tucson remains limited), and an evidence-based-treatment gap that the meth shift has exposed. The system covers more than it used to. It does not yet cover what the current moment requires.